Related Experiment Videos
Sural/radial nerve amplitude ratio: reference values in healthy subjects
Berno U H Overbeek1, Nens van Alfen, Jose A Bor
1Department of Clinical Neurophysiology, Radboud University Nijmegen Medical Center, The Netherlands.
Muscle & Nerve
|August 24, 2005
Summary
The sural/radial nerve amplitude ratio (SRAR) is a reliable measure for detecting early axonal polyneuropathy, unaffected by age, sex, or calculation method. Bilateral measurements are advised for robust results in clinical practice.
Area of Science:
- Neuroscience
- Clinical Electrophysiology
Background:
- The sural/radial nerve amplitude ratio (SRAR) is a proposed sensitive indicator for early axonal polyneuropathy.
- Previous research has not fully addressed the impact of sex differences or varied calculation methodologies on SRAR.
- Establishing reliable reference values for SRAR is crucial for its application in clinical practice.
Purpose of the Study:
- To determine reference values and variability of the SRAR in healthy adults.
- To assess the influence of sex, age, weight, and calculation methods on SRAR.
- To recommend optimal methods for SRAR measurement and interpretation.
Main Methods:
- Nerve conduction studies measuring sural and superficial radial sensory nerve action potentials in 106 healthy adults.
- Correlation analysis with epidemiological variables (age, weight, sex).
- Calculation of SRAR using multiple methods and assessment of its robustness.
Main Results:
- The SRAR was found to be a robust measure, independent of age, weight, sex, or calculation method.
- Bilateral measurements of nerve amplitudes are recommended for improved reliability.
- A cut-off value (5th percentile) of 0.2 was established in healthy subjects, which is lower than previously reported.
Conclusions:
- The SRAR is a stable and reliable electrophysiological marker for early axonal polyneuropathy detection.
- Standardized bilateral measurements and a lower cut-off value should be considered for clinical use.
- Further research is warranted to fully elucidate the clinical utility of SRAR in diagnosing early-stage axonal polyneuropathies.